secwatch / observer
8-K filed September 15, 2023, 7:59 PM ET ticker ROIV CIK 0001635088
other material confidence high sentiment neutral materiality 0.15

Shareholders elect two Class II directors and ratify EY as auditor at 2023 AGM

Roivant Sciences Ltd.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Roivant Sciences Ltd. shareholders approved Election of Class II Directors at the 2023-09-12 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-09-12
Exact text from the filing
Shareholders elected the individuals named below to serve as Class II directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2026, and until their successors are duly elected and qualified, or until such director’s earlier death, resignation or removal.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Roivant Sciences Ltd. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm and as auditor for statutory purposes under the Bermuda Companies Act at the 2023-09-12 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-09-12
Exact text from the filing
Shareholders ratified the appointment of Ernst & Young LLP (“EY”) to serve as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2024, and to appoint EY as the Company’s auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for the fiscal year ending March 31, 2024.
View on SEC.gov

352 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR
accession 0001140361-23-044154
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.